



New Cancer Immunotherapy Agents in Development

Wednesday, November 9, 2016

Co-Chairs:

Adrian Bot, MD, PhD – *Kite Pharma, Inc.*

Daniel S. Chen, MD, PhD – *Genentech*

Roger D. Dansey, MD – *Merck & Co., Inc.*

Ramy Ibrahim, MD[♦] – *The Parker Institute for Cancer Immunotherapy*

[♦]*Formerly at AstraZeneca*

Salil Patel, PhD – *Bristol-Myers Squibb*

11:00 – 11:10 a.m.

Welcome & Introductions

Daniel Chen, MD, PhD – *Genentech*

Session I: Clinical New Agents in Development

Moderator:

Adrian Bot, MD, PhD – *Kite Pharma, Inc.*

11:10 – 11:15 a.m.

Anti-Semaphorin4D VX15/2503 in Combination with Ipilimumab or Antibody to PD-1 or PD-L1

Elizabeth Evans, PhD – *Vaccinex, Inc.*
Vice President Preclinical Research

11:15 – 11:20 a.m.

IMO-2125, an Investigational Intratumoral Toll-Like Receptor 9 Agonist, Modulates the Tumor Microenvironment to Enhance Anti-tumor Immunity

Mark Cornfeld, MD, MPH – *Idera Pharmaceuticals*
Vice President, Oncology Medical Lead

11:20 – 11:25 a.m.

Cobimetinib in Combination with Atezolizumab

Edward Cha, MD, PhD – *Genentech*
Associate Medical Director

11:25 – 11:30 a.m.

Combination Strategy for Varlilumab, An Agonist Anti-CD27 Monoclonal Antibody

Thomas Davis, MD – *Celldex Therapeutics, Inc.*
Chief Medical Officer

11:30 – 11:35 a.m.

Safety of the Natural Killer (NK) Cell-Targeted Anti-KIR Antibody, Lirilumab (liri), in Combination with Nivolumab (nivo) or Ipilimumab (ipi) in Two Phase 1 Studies in Advanced Refractory Solid Tumors

Rom S. Leidner, MD – *Earle A. Chiles Research Institute, Providence Cancer Center*
Attending Physician



- 11:35 – 11:40 a.m. **A CD122-Biased Agonist Increases CD8+T Cells and Natural Killer Cells in the Tumor Microenvironment; Making Cold Tumors Hot with NKTR-214**
Adi Diab, MD – *The University of Texas MD Anderson Cancer Center*
Assistant Professor
- 11:40 – 11:45 a.m. **Activated Natural Killer (aNK) Cell Therapy**
Patrick Soon-Shiong, MD, FRCS, FACS – *NantKwest*
CEO & Chairman

Session II: Pre-Clinical New Agents in Development

Moderator:

Adrian Bot, MD, PhD – *Kite Pharma, Inc.*

- 11:45 – 11:50 a.m. **CD3-EGFR ProbodTM T Cell-Engaging Bispecific Induces Tumor Regressions and Substantially Increases Safety Window in Preclinical Studies**
Bryan A. Irving, PhD – *CytomX Therapeutics, Inc.*
Vice President
- 11:50 – 11:55 a.m. **PRS-343, a CD137 (4-1BB)/HER2 Bispecific**
Shane A. Olwill, PhD – *Pieris Pharmaceuticals, Inc.*
VP Development and Head of Immuno-oncology
- 11:55 – Noon **pLADD: Personalized, Live, Attenuated Double-Deleted Listeria Monocytogenes**
Thomas W. Dubensky Jr., PhD – *Aduro Biotech*
Chief Scientific Officer
- Noon – 12:05 a.m. **CA170: A Small Molecule Orally Available Checkpoint Inhibitor**
David Tuck, MD – *Curis*
Chief Medical Officer
- 12:05 – 12:10 p.m. **LAG-3Ig (IMP321) in Combination with Anti-PD-1 Therapy**
Frederic Triebel, MD, PhD – *Prima Biomed*
Chief Scientific Officer and Chief Medical Officer
- 12:10 – 12:15 p.m. **Agent A - PD-1 DNR-41BB: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation**
Prasad S. Adusumilli, MD, FACS, FCCP – *Memorial Sloan Kettering Cancer Center*
Deputy Chief, Translational and Clinical Research
- 12:15 – 12:20 p.m. **The Immunoreceptor TIGIT Regulates Anti-Tumor Immunity**
Jane Grogan, PhD – *Genentech*
Principle Scientist
- 12:20 – 12:45 p.m. **Audience Q & A**
- 12:45 – 1:30 p.m. *Lunch*



Session III: Strategic Considerations of Combinations and Biomarkers in New Agent Development

1:30 – 2:00 p.m.

Combinations & Biomarkers

Charles G. Drake, MD, PhD – *Columbia University Herbert Irving Comprehensive Cancer Center*

2:00 – 3:25 p.m.

Extended Panel Discussion

Moderator: Daniel S. Chen, MD, PhD – *Genentech*

Clinical Representative:

Charles G. Drake, MD, PhD – *Columbia University Herbert Irving Comprehensive Cancer Center*

Translational Representative:

Gordon J. Freeman, PhD – *Dana-Farber Cancer Institute*

FDA Representatives:

Raj K. Puri, MD, PhD – *U.S. Food & Drug Administration*

Marc Theoret, MD – *U.S. Food & Drug Administration*

3:25 – 3:30 p.m.

Closing Remarks

Roger D. Dansey, MD – *Merck & Co., Inc.*

Social Activity

3:30 – 4:30 p.m.

Drug Development Networking Reception